Bibliography
- Cech TR, Bass BL. Biological catalysis by RNA. Annu Rev Biochem 1986;55:599-629
- Fire A, Xu S, Montgomery MK, et al. Potent and specific genetic interference by doublestranded RNA in Caenorhabditis elegans. Nature 1998;391(6669):806-11
- Elbashir SM, Harborth J, Lendeckel W, et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001;411(6836):494-8
- McCaffrey AP, Meuse L, Pham TT, et al. RNA interference in adult mice. Nature 2002;418(6893):38-9
- Davidson BL, McCray PB Jr. Current prospects for RNA interference-based therapies. Nat Rev Genet 2011;12(5):329-40
- Castanotto D, Rossi JJ. The promises and pitfalls of RNA-interference-based therapeutics. Nature 2009;457(7228):426-33
- Meister G, Tuschl T. Mechanisms of gene silencing by double-stranded RNA. Nature 2004;431(7006):343-9
- Kim VN. MicroRNA biogenesis: coordinated cropping and dicing. Nat Rev Mol Cell Biol 2005;6(5):376-85
- Borchert GM, Lanier W, Davidson BL. RNA polymerase III transcribes human microRNAs. Nat Struct Mol Biol 2006;13(12):1097-101
- Seyhan AA. RNAi: a potential new class of therapeutic for human genetic disease. Hum Genet 2011;130(5):583-605
- Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet 2008;9(2):102-14
- Du T, Zamore PD. microPrimer: the biogenesis and function of microRNA. Development 2005;132(21):4645-52
- Lecellier CH, Dunoyer P, Arar K, et al. A cellular microRNA mediates antiviral defense in human cells. Science 2005;308(5721):557-60
- Dykxhoorn DM, Palliser D, Lieberman J. The silent treatment: siRNAs as small molecule drugs. Gene Ther 2006;13(6):541-52
- Okamura K, Ishizuka A, Siomi H, Siomi MC. Distinct roles for Argonaute proteins in small RNA-directed RNA cleavage pathways. Genes Dev 2004;18(14):1655-66
- Martinez J, Tuschl T. RISC is a 5' phosphomonoester-producing RNA endonuclease. Genes Dev 2004;18(9):975-80
- Saxena S, Jónsson ZO, Dutta A. Small RNAs with imperfect match to endogenous mRNA repress translation. Implications for off-target activity of small inhibitory RNA in mammalian cells. J Biol Chem 2003;278(45):44312-19
- Croce CM. Oncogenes and cancer. N Engl J Med 2008;358(5):502-11
- Lu Z, Bast RC Jr. Tumor suppressor genes. Cancer Treat Res 2009;149:109-29
- Tan FL, Yin JQ. Application of RNAi to cancer research and therapy. Front Biosci 2005;10:1946-60
- Harper SQ, Staber PD, He X, et al. RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc Natl Acad Sci USA 2005;102(16):5820-5
- Prasanthi JR, Larson T, Schommer J, Ghribi O. Silencing GADD153/CHOP gene expression protects against Alzheimer's disease-like pathology induced by 27-hydroxycholesterol in rabbit hippocampus. PLoS ONE 2011;6(10):e26420
- Sapru MK, Yates JW, Hogan S, et al. Silencing of human alpha-synuclein in vitro and in rat brain using lentiviral-mediated RNAi. Exp Neurol 2006;198(2):382-90
- Ralph GS, Radcliffe PA, Day DM, et al. Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model. Nat Med 2005;11(4):429-33
- Li M, Li H, Rossi JJ. RNAi in combination with a ribozyme and TAR decoy for treatment of HIV infection in hematopoietic cell gene therapy. Ann N Y Acad Sci 2006;1082:172-9
- He F, Chen EQ, Liu L, et al. Inhibition of hepatitis B Virus replication by hepatocyte nuclear factor 4-alpha specific short hairpin RNA. Liver Int 2012;32(5):742-51
- Czech MP, Aouadi M, Tesz GJ. RNAi-based therapeutic strategies for metabolic disease. Nat Rev Endocrinol 2011;7(8):473-84
- Gary DJ, Puri N, Won YY. Polymer-based siRNA delivery: perspectives on the fundamental and phenomenological distinctions from polymer-based DNAdelivery. J Control Release 2007;121(1-2):64-73
- Shen H, Sun T, Ferrari M. Nanovector delivery of siRNA for cancer therapy. Cancer Gene Ther 2012;19(6):367-73
- Wang J, Lu Z, Wientjes MG, Au JLS. Delivery of siRNA Therapeutics: barriers and Carriers. AAPS J 2010;12(4):492-503
- Soutschek J, Akinc A, Bramlage B, et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004;432(7014):173-8
- Maeda H. Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. Bioconjug Chem 2010;21(5):797-802
- Rand TA, Ginalski K, Grishin NV, Wang X. Biochemical identification of Argonaute 2 as the sole protein required for RNA-induced silencing complex activity. Proc Natl Acad Sci USA 2004;101(40):14385-9
- Weissmann G. Lysosomes. N Engl J Med 1965;273(21):1143-9
- Shukla S, Sumaria CS, Pradeepkumar PI. Exploring chemical modifications for siRNA therapeutics: a structural and functional outlook. ChemMedChem 2010;5(3):328-49
- Kim SS, Garg H, Joshi A, Manjunath N. Strategies for targeted nonviral delivery of siRNAs in vivo. Trends Mol Med 2009;15(11):491-500
- Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 2005;5(3):161-71
- Tao L, Hu W, Liu Y, et al. Shape-specific polymeric nanomedicine: emerging opportunities and challenges. Exp Biol Med (Maywood) 2011;236(1):20-9
- Hornung V, Guenthner-Biller M, Bourquin C, et al. Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med 2005;11(3):263-70
- Couto LB, High KA. Viral vector-mediated RNA interference. Curr Opin Pharmacol 2010;10(5):534-42
- Jafari M, Chen P. Peptide mediated siRNA delivery. Curr Top Med Chem 2009;9(12):1088-97
- Choi KM, Choi SH, Jeon H, et al. Chimeric capsid protein as a nanocarrier for siRNA delivery: stability and cellular uptake of encapsulated siRNA. ACS Nano 2011;5(11):8690-9
- Vornlocher HP. Antibody-directed cell-type-specific delivery of siRNA. Trends Mol Med 2006;12(1):1-3
- Wu SY, McMillan NA. Lipidic systems for in vivo siRNA delivery. AAPS J 2009;11(4):639-52
- Kim WJ, Kim SW. Efficient siRNA delivery with non-viral polymeric vehicles. Pharm Res 2009;26(3):657-66
- Braun GB, Pallaoro A, Wu G, et al. Laser-Activated Gene Silencing via Gold Nanoshell siRNA Conjugates. ACS Nano 2009;3(7):2007-15
- Biswal BK, Debata NB, Verma RS. Development of a targeted siRNA delivery system using FOL-PEG-PEI conjugate. Mol Biol Rep 2010;37(6):2919-26
- Hwa Kim S, Hoon Jeong J, Chul Cho K, et al. Target-specific gene silencing by siRNA plasmid DNA complexed with folate-modified poly(ethylenimine). J Control Release 2005;104(1):223-32
- Andón FT, Fadeel B. Programmed cell death: molecular mechanisms and implications for safety assessment of nanomaterials. Acc Chem Res 2013;46(3):733-42
- Stern ST, Adiseshaiah PP, Crist RM. Autophagy and lysosomal dysfunction as emerging mechanisms of nanomaterial toxicity. Part Fibre Toxicol 2012;9:20
- Pelkmans L, Kartenbeck J, Helenius A. Caveolar endocytosis of simian virus 40 reveals a new two-step vesicular-transport pathway to the ER. Nat Cell Biol 2001;3(5):473-83
- Cohen AW, Hnasko R, Schubert W, Lisanti MP. Role of caveolae and caveolins in health and disease. Physiol Rev 2004;84(4):1341-79
- Dauty E, Remy JS, Zuber G, Behr JP. Intracellular delivery of nanometric DNA particles via the folate receptor. Bioconjug Chem 2002;13(4):831-9
- Urban-Klein B, Werth S, Abuharbeid S, et al. RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther 2005;12(5):461-6
- Moriguchi R, Kogure K, Akita H, et al. A multifunctional envelope-type nano device for novel gene delivery of siRNA plasmids. Int J Pharm 2005;301(1-2):277-85
- Kim HS, Han HD, Armaiz-Pena GN, et al. Functional roles of Src and Fgr in ovarian carcinoma. Clin Cancer Res 2011;17(7):1713-21
- Monteagudo S, Perez-Martinez FC, Perez-Carrion MD, et al. Inhibition of p42 MAPK using a nonviral vector-delivered siRNA potentiates the anti-tumor effect of metformin in prostate cancer cells. Nanomedicine (Lond) 2012;7(4):493-506
- Khalil IA, Kogure K, Akita H, Harashima H. Uptake pathways and subsequent intracellular trafficking in nonviral gene delivery. Pharmacol Rev 2006;58(1):32-45
- Fischer D, Bieber T, Li Y, et al. A novel non-viral vector for DNA delivery based on low molecular weight, branched polyethylenimine: effect of molecular weight on transfection efficiency and cytotoxicity. Pharm Res 1999;16(8):1273-9
- Hunter AC. Molecular hurdles in polyfectin design and mechanistic background to polycation induced cytotoxicity. Adv Drug Deliv Rev 2006;58(14):1523-31
- Arote R, Kim TH, Kim YK, et al. A biodegradable poly(ester amine)-based on polycaprolactone and polyethylenimine as a gene carrier. Biomaterials 2007;28(4):735-44
- Kim YH, Park JH, Lee M, et al. Polyethylenimine with acid-labile linkages as a biodegradable gene carrier. J Control Release 2005;103(1):209-19
- Mao S, Neu M, Germershaus O, et al. Influence of polyethylene glycol chain length on the physicochemical and biological properties of poly(ethylene imine)-graft-poly(ethylene glycol) block copolymer/SiRNA polyplexes. Bioconjug Chem 2006;17(5):1209-18
- Boussif O, Lezoualc'h F, Zanta MA, et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci USA 1995;92(16):7297-301
- Grzelinski M, Urban-Klein B, Martens T, et al. RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts. Hum Gene Ther 2006;17(7):751-66
- Hobel S, Koburger I, John M, et al. Polyethylenimine/small interfering RNA-mediated knockdown of vascular endothelial growth factor in vivo exerts anti-tumor effects synergistically with Bevacizumab. J Gene Med 2010;12(3):287-300
- Grayson AC, Doody AM, Putnam D. Biophysical and structural characterization of polyethylenimine-mediated siRNA delivery in vitro. Pharm Res 2006;23(8):1868-76
- Jeong GJ, Byun HM, Kim JM, et al. Biodistribution and tissue expression kinetics of plasmid DNA complexed with polyethylenimines of different molecular weight and structure. J Control Release 2007;118(1):118-25
- Goula D, Remy JS, Erbacher P, et al. Size, diffusibility and transfection performance of linear PEI/DNA complexes in the mouse central nervous system. Gene Ther 1998;5(5):712-17
- Behr JP. The proton sponge: a trick to enter cells the viruses did not exploit. Chimia (Aarau) 1997;51(1-2):34-6
- Harvey WR. Physiology of V-ATPases. J Exp Biol 1992;172:1-17
- Won YY, Sharma R, Konieczny SF. Missing pieces in understanding the intracellular trafficking of polycation/DNA complexes. J Control Release 2009;139(2):88-93
- Yue Y, Jin F, Deng R, et al. Revisit complexation between. DNA and polyethylenimine–effect of length of free polycationic chains on gene transfection. J Control Release 2011;152(1):143-51
- Allende D, Simon SA, McIntosh TJ. Melittin-induced bilayer leakage depends on lipid material properties: evidence for toroidal pores. Biophys J 2005;88(3):1828-37
- Yang L, Harroun TA, Weiss TM, et al. Barrel-stave model or toroidal model? A case study on melittin pores. Biophys J 2001;81(3):1475-85
- Ogris M, Carlisle RC, Bettinger T, Seymour LW. Melittin enables efficient vesicular escape and enhanced nuclear access of nonviral gene delivery vectors. J Biol Chem 2001;276(50):47550-5
- Høgset A, Prasmickaite L, Selbo PK, et al. Photochemical internalisation in drug and gene delivery. Adv Drug Deliv Rev 2004;56(1):95-115
- Ndoye A, Dolivet G, Høgset A, et al. Eradication of p53-mutated head and neck squamous cell carcinoma xenografts using nonviral p53 gene therapy and photochemical internalization. Mol Ther 2006;13(6):1156-62
- Höbel S, Koburger I, John M, et al. Polyethylenimine/small interfering RNA-mediated knockdown of vascular endothelial growth factor in vivo exerts anti-tumor effects synergistically with Bevacizumab. J Gene Med 2010;12(3):287-300
- Hendruschk S, Wiedemuth R, Aigner A, et al. RNA interference targeting survivin exerts antitumoral effects in vitro and in established glioma xenografts in vivo. Neuro Oncol 2011;13(10):1074-89
- Bonnet ME, Erbacher P, Bolcato-Bellemin AL. Systemic delivery of DNA or siRNA mediated by linear polyethylenimine (L-PEI) does not induce an inflammatory response. Pharm Res 2008;25(12):2972-82
- Kawakami S, Ito Y, Charoensit P, et al. Evaluation of proinflammatory cytokine production induced by linear and branched polyethylenimine/plasmid DNA complexes in mice. J Pharmacol Exp Ther 2006;317(12):1382-90
- Tousignant JD, Gates AL, Ingram LA, et al. Comprehensive analysis of the acute toxicities induced by systemic administration of cationic lipid:plasmid DNA complexes in mice. Hum Gene Ther 2000;11(18):2493-513
- Tousignant JD, Zhao H, Yew NS, et al. DNA sequences in cationic lipid:pDNA-mediated systemic toxicities. Hum Gene Ther 2003;14(3):203-14
- Song WJ, Du JZ, Sun TM, et al. Gold nanoparticles capped with polyethyleneimine for enhanced siRNA delivery. Small 2010;6(2):239-46
- Zhang L, Lu Z, Zhao Q, et al. Enhanced chemotherapy efficacy by sequential delivery of siRNA and anticancer drugs using PEI-grafted graphene oxide. Small 2011;7(4):460-4
- Lu ZX, Liu LT, Qi XR. Development of small interfering RNA delivery system using PEIPEG-APRPG polymer for antiangiogenic vascular endothelial growth factor tumor-targeted therapy. Int J Nanomedicine 2011;6:1661-73
- Salvati A, Pitek AS, Monopoli MP, et al. Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. Nat Nanotechnol 2013;8(2):137-43
- Genetic Immunity. DermaVir Patch (LC002) in HIV-1 Infected Treatment-naive Patients. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2012 Oct 18]. Available from: http://clinicaltrials.gov/show/NCT00711230 NLM Identifier: NCT00711230
- BioCancell Therapeutics Israel Ltd. Phase 2b, Trial of Intravesical DTA-H19/PEI in Patients With Intermediate-Risk Superficial Bladder Cancer. Bethesda (MD): National Library of Medicine (US). 2000-. Available from: http://clinicaltrials.gov/show/NCT00595088 NLM Identifier: NCT00595088 Cited October 18 2012
- Roy K, Mao HQ, Huang SK, Leong KW. Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat Med 1999;5(4):387-91
- Kumar M, Behera AK, Lockey RF, et al. Intranasal gene transfer by chitosan-DNA nanospheres protects BALB/c mice against acute respiratory syncytial virus infection. Hum Gene Ther 2002;13(12):1415-25
- Dai H, Jiang X, Tan GC, et al. Chitosan-DNA nanoparticles delivered by intrabiliary infusion enhance liver-targeted gene delivery. Int J Nanomedicine 2006;1(4):507-22
- Jean M, Alameh M, Buschmann MD, Merzouki A. Effective and safe gene-based delivery of GLP-1 using chitosan/plasmid-DNA therapeutic nanocomplexes in an animal model of type 2 diabetes. Gene Ther 2011;18(8):807-16
- Pille JY, Li H, Blot E, et al. Intravenous delivery of anti-RhoA small interfering RNA loaded in nanoparticles of chitosan in mice: safety and efficacy in xenografted aggressive breast cancer. Hum Gene Ther 2006;17(10):1019-26
- Howard KA, Paludan SR, Behlke MA, et al. Chitosan/siRNA nanoparticle-mediated TNFalpha knockdown in peritoneal macrophages for anti-inflammatory treatment in a murine arthritis model. Mol Ther 2009;17(1):162-8
- Li BJ, Tang Q, Cheng D, et al. Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque. Nature Med 2005;11(9):944-51
- Luo Y, Zhai X, Ma C, et al. An inhalable beta 2-adrenoceptor ligand-directed guanidinylated chitosan carrier for targeted delivery of siRNA to lung. J Control Release 2012;162(1):28-36
- Mao S, Sun W, Kissel T. Chitosan-based formulations for delivery of DNA and siRNA. Adv Drug Deliv Rev 2010;62(1):12-27
- Garcia-Fuentes M, Alonso MJ. Chitosan-based drug nanocarriers: where do we stand? J Control Release 2012;161(2):496-504
- Anthonsen MW, Smidsrod O. Hydrogen ion titration of chitosans with varying degrees of N-acetylation by monitoring induced 1H-NMR chemical shifts. Carbohydrate Polym 1995;26(4):303-5
- Liu WG, De Yao K, Liu QG. Formation of a DNA/N-dodecylated chitosan complex and salt-induced gene delivery. J Appl Polym Sci 2001;82(14):3391-5
- Thanou M, Florea BI, Geldof M, et al. Quaternized chitosan oligomers as novel gene delivery vectors in epithelial cell lines. Biomaterials 2002;23(1):153-9
- Rojanarata T, Opanasopit P, Techaarpornkul S, et al. Chitosan-thiamine pyrophosphate as a novel carrier for siRNA delivery. Pharm Res 2008;25(12):2807-14
- Malmo J, Sorgard H, Varum KM, Strand SP. siRNA delivery with chitosan nanoparticles: molecular properties favoring efficient gene silencing. J Control Release 2011;158(2):261-8
- Wei W, Lv PP, Chen XM, et al. Codelivery of mTERT siRNA and paclitaxel by chitosan-based nanoparticles promoted synergistic tumor suppression. Biomaterials 2013;34(15):3912-23
- Nawroth I, Alsner J, Behlke MA, et al. Intraperitoneal administration of chitosan/DsiRNA nanoparticles targeting TNFα prevents radiation-induced fibrosis. Radiother Oncol 2010;97(1):143-8
- Shu XZ, Zhu KJ. The influence of multivalent phosphate structure on the properties of ionically cross-linked chitosan films for controlled drug release. Eur J Pharm Biopharm 2002;54(2):235-43
- Lee MK, Chun SK, Choi WJ, et al. The use of chitosan as a condensing agent to enhance emulsion-mediated gene transfer. Biomaterials 2005;26(14):2147-56
- Boateng JS, Matthews KH, Stevens HN, Eccleston GM. Wound healing dressings and drug delivery systems: a review. J Pharm Sci 2008;97(8):2892-923
- Lee J, Yun KS, Choi CS, et al. T Cell-Specific siRNA Delivery Using Antibody-Conjugated Chitosan Nanoparticles. Bioconjug Chem 2012;23(6):1174-80
- Han HD, Mangala LS, Lee JW, et al. Targeted gene silencing using RGD-labeled chitosan nanoparticles. Clin Cancer Res 2010;16(15):3910-22
- Prego C, Garcia M, Torres D, Alonso MJ. Transmucosal macromolecular drug delivery. J Control Release 2005;101(1-3):151-62
- Mishra S, Webster P, Davis ME. PEGylation significantly affects cellular uptake and intracellular trafficking of non-viral gene delivery particles. Eur J Cell Biol 2004;83(3):97-111
- Hatakeyama H, Akita H, Harashima H. A multifunctional envelope type nano device (MEND) for gene delivery to tumours based on the EPR effect: a strategy for overcoming the PEG dilemma. Adv Drug Deliv Rev 2011;63(3):152-60
- Li W, Huang Z, MacKay JA, et al. Low-pH-sensitive poly(ethylene glycol) (PEG)-stabilized plasmid nanolipoparticles: effects of PEG chain length, lipid composition and assembly conditions on gene delivery. J Gene Med 2005;7(1):67-79
- Moghimi SM, Andersen AJ, Hashemi SH, et al. Complement activation cascade triggered by PEG-PL engineered nanomedicines and carbon nanotubes: the challenges ahead. J Control Release 2010;146(2):175-81
- Veronese FM, Pasut G. PEGylation, successful approach to drug delivery. Drug Discov Today 2005;10(21):1451-8
- Kievit FM, Veiseh O, Bhattarai N, et al. PEI-PEG-Chitosan Copolymer Coated Iron Oxide Nanoparticles for Safe Gene Delivery: synthesis, complexation, and transfection. Adv Funct Mater 2009;19(14):2244-51
- Jere D, Jiang HL, Kim YK, et al. Chitosan-graft-polyethylenimine for Akt1 siRNA delivery to lung cancer cells. Int J Pharm 2009;378(1-2):194-200
- Ping Y, Liu C, Zhang Z, et al. Chitosan-graft-(PEI- beta-cyclodextrin) copolymers and their supramolecular PEGylation for DNA and siRNA delivery. Biomaterials 2011;32(32):8328-41
- Malhotra M, Lane C, Tomaro-Duchesneau C, et al. A novel method for synthesizing PEGylated chitosan nanoparticles: strategy, preparation, and in vitro analysis. Int J Nanomedicine 2011;6:485-94
- Lv H, Zhang S, Wang B, et al. Toxicity of cationic lipids and cationic polymers in gene delivery. J Control Release 2006;114(1):100-9
- Weber ND, Merkel OM, Kissel T, Munoz-Fernandez MA. PEGylated poly(ethylene imine) copolymer-delivered siRNA inhibits HIV replication in vitro. J Control Release 2012;157(1):55-63
- Huang Y, Lin D, Jiang Q, et al. Binary and ternary complexes based on polycaprolactonegraft-poly (N, N-dimethylaminoethyl methacrylate) for targeted siRNA delivery. Biomaterials 2012;33(18):4653-64
- Zamora MR, Budev M, Rolfe M, et al. RNA interference therapy in lung transplant patients infected with respiratory syncytial virus. Am J Respir Crit Care Med 2011;183(4):531-8
- Li MJ, Kim J, Li S, et al. Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolar-localizing TAR decoy. Mol Ther 2005;12(5):900-9
- Nguyen QD, Shah SM, Hafiz G, et al. A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2006;113(9):1522.e1-1522.e14
- Shoshani T, Faerman A, Mett I. Identification of a novel hypoxia-inducible factor 1-responsive gene, RTP801, involved in apoptosis. Mol Cell Biol 2002;22(7):2283-93
- Pechala's Reports. Tekmira Pharmaceuticals CP (TEKMIRA) 12 months forecast. 2013.